The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes Across a Wide Range of Concentrations

PURPOSE: PLX4032 (RG7204), an oncogenic BRAF kinase inhibitor undergoing clinical evaluation, has high response rates in early clinical trials in patients with advanced BRAF(V600E) mutant melanoma. Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Comin-Anduix, Begoña, Chodon, Thinle, Sazegar, Hooman, Matsunaga, Douglas, Mock, Stephen, Jalil, Jason, Escuin-Ordinas, Helena, Chmielowski, Bartosz, Koya, Richard C., Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057460/
https://ncbi.nlm.nih.gov/pubmed/21169256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1911
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados